Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 83,634 | 250,728 | 178,700 | 215,433 | 158,447 |
| Marketable Securities | 434,970 | 160,915 | 158,536 | 156,231 | 111,551 |
| Receivables | 10,259 | 19,064 | 8,194 | 3,996 | 1,276 |
| TOTAL | $588,435 | $471,171 | $377,065 | $382,062 | $275,544 |
| Non-Current Assets | |||||
| PPE Net | 10,930 | 11,348 | 11,191 | 11,324 | 12,104 |
| Investments And Advances | 3,630 | 4,895 | 5,112 | 20,045 | 21,211 |
| Intangibles | 13,523 | 13,660 | 13,797 | 13,934 | 14,071 |
| Other Non-Current Assets | 38,345 | 38,699 | 30,650 | 15,821 | 15,992 |
| TOTAL | $66,429 | $68,602 | $60,749 | $61,123 | $63,377 |
| Total Assets | $654,863 | $539,773 | $437,814 | $443,185 | $338,921 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 26,743 | 21,847 | 24,328 | 17,729 | 11,283 |
| Accrued Expenses | 7,371 | 9,950 | 5,841 | 6,871 | 5,061 |
| TOTAL | $41,540 | $41,706 | $41,263 | $37,982 | $32,295 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 4,516 | 4,152 | 13,719 | 12,825 |
| Deferred Revenues | 5,030 | 7,579 | 8,830 | 11,182 | 13,818 |
| Other Non-Current Liabilities | 31,573 | 32,261 | 68,247 | 205,438 | 106,274 |
| TOTAL | $31,718 | $36,926 | $72,551 | $218,843 | $118,772 |
| Total Liabilities | $73,257 | $78,632 | $113,814 | $256,825 | $151,067 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,443 | 17,296 | 14,112 | 13,954 | 13,169 |
| Common Shares | 209 | 187 | 168 | 159 | 146 |
| Retained earnings | -960,599 | -906,197 | -881,859 | -901,030 | -772,327 |
| Other shareholders' equity | -265 | -256 | -152 | -514 | 2,072 |
| TOTAL | $581,606 | $461,141 | $324,000 | $186,361 | $187,854 |
| Total Liabilities And Equity | $654,863 | $539,772 | $437,814 | $443,185 | $338,921 |